Long-Term Safety and Efficacy of Bimekizumab in Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies.
Baraliakos X, Deodhar A, van der Heijde D, Van den Bosch F, Magrey M, Maksymowych WP, Tomita T, Xu H, Massow U, Vaux T, Prajapati C, Manente M, Marten A, Gensler LS.
Baraliakos X, et al. Among authors: tomita t.
Rheumatology (Oxford). 2025 Jan 11:keaf009. doi: 10.1093/rheumatology/keaf009. Online ahead of print.
Rheumatology (Oxford). 2025.
PMID: 39798135